Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 234 vs Pembrolizumab in Early-stage Non-squamous NSCLC
NCT06430866Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of abp 234 in non-small cell lung cancer (NSCLC), sponsored by Amgen. Started Sep 2024; status: active, not recruiting.
02
Drugs
abp 234
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06430866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430866.